These insights pave the way for nanomedicine-based translation, especially the use of mesoporous silica nanoparticles, liposomes, or lipid-based nanocarriers for PD-1-targeted immune checkpoint blockade, with enhanced tumor specificity and reduced off-target effects (33). This evidence concerns the gene PDCD1 and neoplasm.